Pharma BD Deal Intelligence

Celgene Corporation / Juno Therapeutics Inc.

2018 · Acquisition/Merger · $9.0B · Complete

Announcement Sentiment

Positive

Outcome Score

Largely worked — most objectives met.

Celgene acquired Juno Therapeutics for approximately $9 billion ($87 per share in cash), gaining full ownership of JCAR017 (lisocabtagene maraleucel), a potentially best-in-class CD19-targeted CAR-T cell therapy in pivotal trials for diffuse large B-cell lymphoma.

Key facts

Announced Jan 22, 2018
Closed Mar 06, 2018
Deal value $9.0B
Deal type Acquisition/Merger
Therapeutic area Gene Therapy, Hematology, Oncology
Indications Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma
Key assets JCAR017 (lisocabtagene maraleucel / liso-cel), CAR-T cell therapy platform, CD19-directed cell therapy pipeline
Mechanism CD19-directed CAR-T cell therapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals